174 related articles for article (PubMed ID: 6698654)
1. A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients.
Chen ML; McGuire WP; Lad TE; Chiou WL
Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):1-6. PubMed ID: 6698654
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate.
Breithaupt H; Küenzlen E
Cancer Treat Rep; 1982 Sep; 66(9):1733-41. PubMed ID: 6956440
[TBL] [Abstract][Full Text] [Related]
3. [Serum monitoring of methotrexate (MTX) and 7-hydroxymethotrexate concentrations in patients treated with MTX using high-pressure liquid chromatography (HPLC) and comparison of serum MTX levels between HPLC method and fluorescence polarization immunoassay (FPIA)].
Sakamoto S; Matsuhisa T; Miyoshi K; Naruse R; Urayama H; Shimokawa T; Okabe K; Toki H; Motoi M; Moriwaki S
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1119-25. PubMed ID: 2053771
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
Chládková J; Hak J; Martínková J; Chládek J
Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
[TBL] [Abstract][Full Text] [Related]
5. Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion.
Chen ML; Chiou WL
J Pharmacokinet Biopharm; 1983 Oct; 11(5):515-27. PubMed ID: 6668557
[TBL] [Abstract][Full Text] [Related]
6. Metabolic interaction between methotrexate and 4'-(9-acridinylamino)methanesulfon-M-anisidide in the rabbit.
Lee YJ; Chan KK
Cancer Res; 1988 Sep; 48(18):5106-11. PubMed ID: 3409236
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of non-renal elimination mechanisms of methotrexate (MTX)].
Erttmann R; Gkanatsas A
Monatsschr Kinderheilkd; 1985 Aug; 133(8):516-9. PubMed ID: 3876505
[TBL] [Abstract][Full Text] [Related]
8. Formation and elimination of 7-hydroxymethotrexate in the rat in vivo after methotrexate administration.
Bremnes RM; Slørdal L; Wist E; Aarbakke J
Cancer Res; 1989 May; 49(9):2460-4. PubMed ID: 2706634
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits after intravenous administration.
Chen ML; Chiou WL
J Pharmacokinet Biopharm; 1983 Oct; 11(5):499-513. PubMed ID: 6668556
[TBL] [Abstract][Full Text] [Related]
10. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone.
Fox RI; Morgan SL; Smith HT; Robbins BA; Choc MG; Baggott JE
Rheumatology (Oxford); 2003 Aug; 42(8):989-94. PubMed ID: 12730515
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of low-dose methotrexate in adult asthmatics.
Glynn-Barnhart AM; Erzurum SC; Leff JA; Martin RJ; Cochran JE; Cott GR; Szefler SJ
Pharmacotherapy; 1992; 12(5):383-90. PubMed ID: 1437699
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent pharmacokinetics of methotrexate and 7-hydroxymethotrexate in the rat in vivo.
Bremnes RM; Slørdal L; Wist E; Aarbakke J
Cancer Res; 1989 Nov; 49(22):6359-64. PubMed ID: 2804982
[TBL] [Abstract][Full Text] [Related]
13. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
14. In vitro approach to 7-hydroxymethotrexate interaction on methotrexate metabolism as tool of pharmacokinetic study.
Fabre G; Cano JP; Catalin J; Just S
Int J Clin Pharmacol Res; 1983; 3(6):475-84. PubMed ID: 6590470
[TBL] [Abstract][Full Text] [Related]
15. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
17. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma.
Wang YM; Sutow WW; Romsdahl MM; Perez C
Cancer Treat Rep; 1979 Mar; 63(3):405-10. PubMed ID: 284845
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.
Widemann BC; Sung E; Anderson L; Salzer WL; Balis FM; Monitjo KS; McCully C; Hawkins M; Adamson PC
J Pharmacol Exp Ther; 2000 Sep; 294(3):894-901. PubMed ID: 10945838
[TBL] [Abstract][Full Text] [Related]
19. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).
Skärby T; Jönsson P; Hjorth L; Behrentz M; Björk O; Forestier E; Jarfelt M; Lönnerholm G; Höglund P
Cancer Chemother Pharmacol; 2003 Apr; 51(4):311-20. PubMed ID: 12721759
[TBL] [Abstract][Full Text] [Related]
20. In vivo methotrexate kinetics and metabolism in human hematopoietic cells. Clinical significance of methotrexate concentrations in erythrocytes.
Schrøder H
Dan Med Bull; 1990 Feb; 37(1):22-40. PubMed ID: 2178886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]